AAV9 Rep-Cap plasmid (serotype 9-specific AAV RC9 plasmids)

GeneMedi's AAV9 Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV9 capsid protein.

You can produce AAV9 particle in 293T cell line in high titer using GeneMedi's AAV9 Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV9 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.

Target products collectionGo to AAV vector system >>



Product Description

Cat.NO Product Name Organization Type Price(In USD)
P-RC13 AAV9 Rep-Cap Plasmid
Academic 935
P-RC13 AAV9 Rep-Cap Plasmid
Industry R&D
(excluding
CRO&CDMO&CXO)
P-RC13 AAV9 Rep-Cap Plasmid
 CRO&CDMO&
CXO&CMC&
Manufacturing company
P-RC13-Kan AAV9 Rep-Cap Plasmid(Kan resistance)
 All
Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Rep-Cap Plasmids and do not provide seed stocks.
P-PK13 AAV9 Vector System
1. AAV9 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
 Academic 2028
P-PK13 AAV9 Vector System
1. AAV9 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Industry R&D
(excluding
CRO&CDMO&CXO)
P-PK13 AAV9 Vector System
1. AAV9 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-PK13-Kan AAV9 Vector System(Kan resistance)
1. AAV9 Rep-Cap Plasmid(Kan resistance), 10mg
2. AAV Helper Plasmid(Kan resistance), 10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), 10mg
 All
Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Vector System and do not provide seed stocks.
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Terms of sale:
For Seed (5ug):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party.

For plasmid production&lification (≥10mg):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party.

Citation

Title Publication Date
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer Molecular Cancer 2022/7/16
N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma Molecular Cancer 2022/5/10
Mitochondrial fission drives neuronal metabolic burden to promote stress susceptibility in male mice Nature Metabolism 2023/11/20
Reduced hepatic bradykinin degradation accounts for cold-induced BAT thermogenesis and WAT browning in male mice Nature Communications 2023/5/2
Ferritinophagy Mediated by Oxidative Stress-Driven Mitochondrial Damage Is Involved in the Polystyrene Nanoparticles-Induced Ferroptosis of Lung Injury ACS nano 2023/12/12
Endothelial response to type I interferon contributes to vasculopathy and fibrosis and predicts disease progression of systemic sclerosis. Arthritis & Rheumatology 2023/7/24
HuR regulates telomerase activity through TERC methylation NATURE COMMUNICATIONS 2018/6/7
Splicing factor YBX1 regulates bone marrow stromal cell fate during aging The EMBO Journal 2023/3/21
Hexavalent chromium induces γH2AX and RAD51 involved in DNA damage repair in BEAS-2B cells by modulating LNC-DHFR-4: 1 Environment International 2023/3/21
Nanoprodrug ratiometrically integrating autophagy inhibitor and genotoxic agent for treatment of triple-negative breast cancer Biomaterials 2022/3/10


Validation data

Picture loading failed.
Figure. Selected transduction results of AAV9 in mouse liver.

Virus and titer: AAV9-GFP, AAV9-pTBG-Luciferase (AAV-Luc), 1.4×1012 vg/ml
Animal: mouse, C57, 2 months
Gene delivery method: tail vein, 100μl
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy, in vivo imaging
Conclusion: intravenous injection of AAV9-pTBG-Luciferase (AAV-Luc) only infects liver cells and no non-specific infection

Picture loading failed.
Figure. Selected transduction results of AAV9-GFP in rat heart (A, B, C) and mouse heart (D).

Virus and titer: AAV9-GFP, 1×1012 vg/ml
Animal: Rat, SD, 2 months (Figure 8A, B, C); mouse, C57, 8 months (Figure 8D)
Infection site: heart
Gene delivery method: myocardial in situ injection, 10μl/site, 5 sites in total (Figure 8A, B, C);intraorbital intravenous injection (Figure 8D)
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

Picture loading failed.
Figure. Selected transduction results of AAV9-GFP in mouse brain.

Virus and titer: AAV9-GFP, 1×1012 vg/ml
Animal: Mouse, C57, 2 months
Infection site: Brain
Gene delivery method: Brain localization injection, 1μl
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

Picture loading failed.
Figure. Selected transduction results of AAV in vitro (in 293T cell line)

Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy

transduction results of AAV2 (left) /AAV-DJ (middle) / AAV9 (right) in tumor
Figure. Selected transduction results of AAV2 (left) /AAV-DJ (middle) / AAV9 (right) in tumor.

Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×1012 vg/ml
Animal: Nude mouse, 2 months
Infection site: Subcutaneous transplant of bowel cancer cells
Gene delivery method: Tumor injection, 10μl/site, 4 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

transduction results of AAV9-GFP in mouse hippocampus
Figure. Selected transduction results of AAV9-GFP in mouse hippocampus.

Virus and titer: AAV9-GFAP-GFP, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: Hippocampus
Gene delivery method: Brain localization injection, 1μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy

transduction of AAV9 in mouse skeletal muscle
Figure. Selected transduction results of AAV9 in mouse skeletal muscle.

Virus and titer: AAV9-Luciferase (AAV-Luc), AAV9-GFP, 1×1012 vg/ml
Animal: Mouse, C57, 2 months
Infection site: Skeletal muscles
Gene delivery method: Muscle in situ injection, 10μl/site, 4 sites in total
Determine assay: 4 weeks post infection, in vivo imaging, frozen section, immunofluorescence microscopy

transduction of AAV9-GFP in mouse muscle
Figure. Selected transduction results of AAV9-GFP in mouse muscle.

Virus and titer: AAV-DJ-GFP, AAV9-GFP, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: Kidney
Gene delivery method: Multiple sites injection in kidney 10μl/site, 6 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

transduction of AAV9-GFP in mouse fat tissue
Figure. Selected transduction results of AAV9-GFP in mouse fat tissue.

Virus and titer: AAV9-GFP, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: Mammary fat pad
Gene delivery method: Breast injection, 10μl/site, 4 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy


Associated products and services


Products & Service Products & Service Information
AAV Packaging service Detail
Promise-ORF™ viral CDNA library Detail
Plasmid DNA Rapid Preparation Service Detail